FibroGen enrolls first patient in pamrevlumab trial for COVID-19

FibroGen (NASDAQ:FGEN) has initiated a Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute COVID-19 infection.

This multicenter trial will enroll approx. 130 patients. The primary objective is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 infection, and patients will be randomized to treatment with pamrevlumab or standard of care in a 1:1 ratio.

The primary efficacy assessment is the proportion of hospitalized COVID-19 patients who have not received mechanical ventilation and/or extracorporeal membrane oxygenation and remain alive at Day 28.

https://seekingalpha.com/news/3585349-fibrogen-enrolls-first-patient-in-pamrevlumab-trial-for-covidminus-19